Medicare AdvantageCoverageLow impact
MA08.151d, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
Independence Blue Cross·Neurology, Geriatrics, Internal Medicine·Medical Policy
Effective date
Nov 13, 2024
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.151d regarding monoclonal antibodies for Alzheimer's disease treatment has been reissued effective November 13, 2024. This policy update affects coverage and billing requirements for specialized Alzheimer's treatments using monoclonal antibody therapies.
Action Required
By December 1, 2024: Billing team should review the complete policy MA08.151d at the IBX medical policy website to understand current coverage criteria and documentation requirements for monoclonal antibody treatments for Alzheimer's disease. Update prior authorization workflows if treating Medicare Advantage patients with these specialized therapies.